

CASE REPORT

Courtesy of Dr. Scott Robinson, MD

SUCCESSFUL TREATMENT OF PROXIMAL PT AND TPT WITH ATHERECTOMY AND ESPRIT™ BTK

INTRODUCTION

A returning patient with a history of previous femoropopliteal bypass presented with significant circumferential wounds extending above right ankle and absent palpable pulses.

PROCEDURAL OVERVIEW

A Diamondback™ 360 Peripheral Orbital Atherectomy System 1.25 solid crown was utilized for vessel preparation due to the calcium burden. Six passes were made starting just proximal to the AT takeoff through proximal segment of PT in low, medium and high speeds.

2.5 mm and 3.0 mm PTA balloons were used to pre-dilate and accurately size the target lesion, and 2.5 mm x 38 mm Esprit™ BTK scaffold was implanted in the proximal right PT. Post-dilation was performed using a 3.0 mm PTA balloon. A second 3.75 mm x 38 mm Esprit™ BTK scaffold was implanted in Tibio-peroneal trunk following pre-dilation and was post-dilated using 4.0 mm PTA balloon. Post procedure angiogram demonstrated brisk flow and patient regained fully palpable pulses.




Figure 1
Pre-Intervention



Figure 2
Post-Intervention

CONCLUSION

*Dr. Robinson “finished strong” with Esprit™ BTK: Delivering drug¹ and providing support², following pre-treatment with balloon angioplasty as evidenced by robust revascularization in the post-intervention angiography. Through 2 years, Esprit™ BTK has shown superior efficacy and sustained benefits^{4,5} compared to balloon angioplasty. With 90.3% freedom from reintervention for Esprit™ BTK patients through 2 years^{4,5,6}, Esprit™ BTK offers a clear advantage over PTA in terms of **sustained vascular patency** and continues to be adopted by physicians around the world to provide optimal care for CLTI patients.*

1. Esprit™ BTK Everolimus Eluting Resorbable Scaffold System Instructions for Use (IFU).

2. Data on File.

3. Excluding platinum markers

4. Varcoe, RL., et al. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. *N Eng J Med* 2024;390:9-19.

5. Brian G. DeRubertis et al., Two-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit™ BTK Drug-eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions, VIVA 2024.

6. Reintervention defined as CD-TLR.

Information contained herein for DISTRIBUTION outside of the U.S. ONLY.
Check the regulatory status of the device(s) in your country or region prior to use.

©2025 Abbott. All rights reserved. MAT-2504925 v1.0

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or [manuals.eifu.abbott](#) and at [csi360.com/product-solutions/instructions-for-use](#) for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. This material is intended for use with healthcare professionals only.

Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Information contained herein for DISTRIBUTION outside of the U.S. ONLY. Check the regulatory status of the device(s) in your country or region prior to use.

Abbott International BV
Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium, Tel: 32.2.714.14.11

™ Indicates a trademark of the Abbott Group of Companies.
[www.cardiovascular.abbott](#)
©2025 Abbott. All rights reserved. MAT-2504925 v1.0

